PL3219729T3 - Przeciwciało monoklonalne przeciwko IL-31 - Google Patents

Przeciwciało monoklonalne przeciwko IL-31

Info

Publication number
PL3219729T3
PL3219729T3 PL17168574T PL17168574T PL3219729T3 PL 3219729 T3 PL3219729 T3 PL 3219729T3 PL 17168574 T PL17168574 T PL 17168574T PL 17168574 T PL17168574 T PL 17168574T PL 3219729 T3 PL3219729 T3 PL 3219729T3
Authority
PL
Poland
Prior art keywords
interleukin
monoclonal antibody
monoclonal
antibody
Prior art date
Application number
PL17168574T
Other languages
English (en)
Inventor
Gary F. BAMMERT
Steven A. DUNHAM
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46704979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3219729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PL3219729T3 publication Critical patent/PL3219729T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17168574T 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31 PL3219729T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510268P 2011-07-21 2011-07-21
PCT/IB2012/053450 WO2013011407A1 (en) 2011-07-21 2012-07-05 Interleukin-31 monoclonal antibody
EP12748547.2A EP2734549B1 (en) 2011-07-21 2012-07-05 Monoclonal antibody against dog interleukin-31
EP17168574.6A EP3219729B1 (en) 2011-07-21 2012-07-05 Interleukin-31 monoclonal antibody

Publications (1)

Publication Number Publication Date
PL3219729T3 true PL3219729T3 (pl) 2021-01-25

Family

ID=46704979

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12748547T PL2734549T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko psiej interleukinie 31
PL17168574T PL3219729T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12748547T PL2734549T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko psiej interleukinie 31

Country Status (24)

Country Link
US (6) US8790651B2 (pl)
EP (4) EP3653645B1 (pl)
JP (1) JP6022563B2 (pl)
KR (2) KR101742928B1 (pl)
CN (2) CN103890009B (pl)
AR (1) AR087281A1 (pl)
AU (2) AU2012285432C1 (pl)
BR (1) BR112014001407A8 (pl)
CA (2) CA2842475C (pl)
CY (2) CY1119475T1 (pl)
DK (2) DK3653645T3 (pl)
ES (2) ES2638340T3 (pl)
HR (2) HRP20171198T1 (pl)
HU (2) HUE034282T2 (pl)
LT (2) LT2734549T (pl)
ME (1) ME02837B (pl)
MX (1) MX349053B (pl)
PL (2) PL2734549T3 (pl)
PT (2) PT3219729T (pl)
RS (2) RS56268B1 (pl)
SI (2) SI3219729T1 (pl)
UY (1) UY34206A (pl)
WO (1) WO2013011407A1 (pl)
ZA (1) ZA201400768B (pl)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045512A2 (en) * 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
SG185465A1 (en) * 2010-05-14 2012-12-28 Amgen Inc High concentration antibody formulations
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
EP4303236A3 (en) * 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
CN104736561B (zh) * 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
AU2013322628B2 (en) * 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
CA2893977C (en) * 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
EP2983711A4 (en) * 2013-04-08 2016-11-23 Cytodyn Inc FELLINED ANTIBODIES AND METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES
EP3024851B1 (en) * 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
PL3065774T3 (pl) * 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
US10023636B2 (en) 2013-12-20 2018-07-17 Intervet Inc. Caninized murine antibodies to human PD-1
RU2016129959A (ru) * 2013-12-30 2018-02-02 Эпимаб Биотерепьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
US11485787B2 (en) * 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
US12103962B2 (en) * 2014-02-06 2024-10-01 X4 Pharmaceuticals (Austria) GmbH E. coli specific antibodies
DK3122775T3 (da) * 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
KR102504758B1 (ko) * 2014-07-16 2023-02-28 트랜스진 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
CA2967222C (en) * 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
WO2016104657A1 (ja) * 2014-12-26 2016-06-30 橋本 正 癌治療剤
EP3252074A4 (en) 2015-01-30 2018-07-11 Saitama Medical University Anti-alk2 antibody
CN107921104A (zh) * 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
WO2016156440A1 (en) * 2015-03-31 2016-10-06 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
AU2016248786B2 (en) * 2015-04-14 2022-01-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient
US11424061B2 (en) * 2015-04-14 2022-08-23 Hanchett Entry Systems, Inc. Solenoid assembly actuation using resonant frequency current controller circuit
CA2987037A1 (en) 2015-05-29 2016-12-08 Amphivena Therapeutics, Inc. Use of cd33/cd3 bispecific tandem diabodies for the treatment of acute myeloid leukemia (aml)
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
BR112018009064A8 (pt) * 2015-11-17 2019-02-26 Jiangsu Hengrui Medicine Co anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
US20190023786A1 (en) * 2016-01-12 2019-01-24 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
US10946078B2 (en) * 2016-04-27 2021-03-16 Benchmark Animal Health Ltd. Treatment of canine atopic dermatitis
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3471759A1 (en) * 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
UY37325A (es) * 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
KR102644544B1 (ko) * 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
CN110167965A (zh) 2016-11-08 2019-08-23 瑞泽恩制药公司 拮抗瘦素受体的抗原结合蛋白
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
CN110325548B (zh) * 2016-12-21 2023-11-17 美莱奥生物制药第三有限公司 抗硬化蛋白抗体在治疗成骨不全症中的用途
EP3574017A1 (en) * 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
MX2019009798A (es) * 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.
WO2018156250A1 (en) * 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JP7314115B2 (ja) * 2017-03-31 2023-07-25 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
CN110650976B (zh) * 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
MY200912A (en) * 2017-05-26 2024-01-23 Glaxosmithkline Ip Dev Ltd Biopharmaceutical Compositions and Related Methods
CA3064298A1 (en) * 2017-06-01 2018-12-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
TWI726228B (zh) * 2017-08-09 2021-05-01 國立臺灣大學 Ｃｄ１４拮抗分子用於治療癌症
JP2020531438A (ja) * 2017-08-16 2020-11-05 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｈｌａ−ｅ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質
MX2020003219A (es) * 2017-09-21 2020-07-20 Imcheck Therapeutics Sas Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019086694A1 (en) 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
WO2019104157A1 (en) * 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
WO2019118512A2 (en) * 2017-12-11 2019-06-20 Ubi Ip Holdings Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
US11834500B2 (en) 2017-12-18 2023-12-05 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
JP2021512917A (ja) * 2018-02-09 2021-05-20 ガルデルマ ホールディング エスエー 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
EP3765500A2 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Interleukin-31 monoclonal antibodies for veterinary use
WO2019177138A1 (ja) * 2018-03-16 2019-09-19 国立大学法人滋賀医科大学 異常ｔｄｐ－４３を分解除去する抗体断片
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
KR20200141461A (ko) * 2018-04-06 2020-12-18 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 작용제 항체를 사용한 치료 방법
AU2019267050B2 (en) * 2018-05-09 2024-09-12 Good T Cells, Inc. Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
CA3100818A1 (en) * 2018-06-13 2019-12-19 Kymab Limited Treatments etc
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
BR112021003173A2 (pt) * 2018-08-20 2021-05-11 Pfizer Inc. anticorpos anti-gdf15, composições e métodos de uso
PE20211072A1 (es) * 2018-09-28 2021-06-09 Chugai Pharmaceutical Co Ltd Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente
WO2020077120A1 (en) * 2018-10-10 2020-04-16 The Board Of Trustees Of The Leland Stanford Junior University BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
CA3120474A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
EP3902921A1 (en) * 2018-12-29 2021-11-03 berYsol GmbH Selenium binding protein 1 detection from body fluids for diagnosis of peracute tissue damage
CN113544153A (zh) * 2019-01-03 2021-10-22 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
JP2022526738A (ja) * 2019-03-21 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ
CA3131705A1 (en) * 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
AU2020268619A1 (en) * 2019-05-03 2021-12-16 National University Of Singapore Treatment and prevention of metabolic diseases
CN110283246A (zh) * 2019-06-20 2019-09-27 长春西诺生物科技有限公司 一种抗猫细小病毒的猫源化基因工程抗体
AU2020329191A1 (en) * 2019-08-12 2022-03-31 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
JP2022545585A (ja) * 2019-08-27 2022-10-28 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
CA3114467C (en) * 2019-08-29 2024-06-11 Remegen Co., Ltd. Anti pd-l1 antibody and use thereof
US11890353B2 (en) * 2019-10-15 2024-02-06 Northwestern University Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
BR112022006590A2 (pt) * 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
US20230002485A1 (en) * 2019-12-06 2023-01-05 Korea Atomic Energy Research Institute Anti-tm4sf4 antibody and uses thereof
WO2021123094A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
AU2020407853A1 (en) 2019-12-20 2022-06-09 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US11987640B2 (en) * 2020-04-07 2024-05-21 Fred Hutchinson Cancer Center Anti-mesothelin antigen-binding molecules and uses thereof
IL297290A (en) 2020-04-17 2022-12-01 Zoetis Services Llc Feline antibody variants
WO2021212081A1 (en) 2020-04-17 2021-10-21 Zoetis Services Llc Canine antibody variants
KR20230005268A (ko) * 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
TWI800824B (zh) * 2020-05-08 2023-05-01 大陸商亘喜生物科技（上海）有限公司 一種抗cd19抗體的抗體及其製備和應用
MX2022014150A (es) 2020-05-11 2023-02-27 Invetx Inc Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso.
AU2021277398A1 (en) * 2020-05-22 2023-02-02 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
KR20230061390A (ko) * 2020-08-05 2023-05-08 신테카인, 인크. Il27 수용체 결합과 관련된 조성물 및 방법
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
FR3113458B1 (fr) 2020-08-21 2022-10-14 Purally Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie
CN116323666A (zh) * 2020-08-21 2023-06-23 建新公司 Fgfr3抗体和使用方法
AU2021349301A1 (en) 2020-09-28 2023-08-24 Zoetis Services Llc Canine antibody variants
AR123645A1 (es) 2020-09-29 2022-12-28 Zoetis Services Llc Variantes de anticuerpos felinos
MX2023004438A (es) 2020-10-15 2023-05-08 Intervet Int Bv Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino.
TW202221039A (zh) 2020-10-19 2022-06-01 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
WO2022094009A1 (en) * 2020-10-30 2022-05-05 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to sars-cov-2 nucleocapsid protein
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
AU2021383841A1 (en) * 2020-11-23 2023-06-22 Scout Bio, Inc. Antigen-binding molecules and uses thereof
IL303732A (en) * 2020-12-18 2023-08-01 Zoetis Services Llc Mutations in constant regions in feline antibodies
JP2024505072A (ja) 2021-01-28 2024-02-02 ゾエティス・サービシーズ・エルエルシー イヌ科動物抗体の定常領域における変異
KR20230136172A (ko) 2021-01-29 2023-09-26 바이엘 애니멀 헬스 게엠베하 자기-관용을 파괴하기 위한 백신 조성물
BR112023016043A2 (pt) 2021-02-22 2023-12-05 Zoetis Services Llc Modelo de prurido induzido por il-31 de cavalo
EP4313309A1 (en) * 2021-03-22 2024-02-07 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022204316A2 (en) * 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
US20220348669A1 (en) * 2021-04-23 2022-11-03 Astrazeneca Ab Treatment of lupus nephritis
WO2023021170A2 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis
MX2024007090A (es) 2021-12-16 2024-08-22 Intervet Int B V Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.
AU2023219227A1 (en) 2022-02-09 2024-08-01 Petmedix Ltd Therapeutic antibodies
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2024057096A1 (en) 2022-09-14 2024-03-21 Ceva Sante Animale Treatment of atopic dermatitis using self-replicating rna expressing il-31
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用
WO2024170486A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-4
WO2024170485A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-13

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
EP1082432A2 (en) * 1998-05-29 2001-03-14 Heska Corporation Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
US6774107B1 (en) 1999-03-18 2004-08-10 Merck Patent Gmbh Protein for blocking platelet adhesion
US6790639B2 (en) 2000-02-29 2004-09-14 Pfizer Inc. Mammalian osteoregulins
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) * 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ES2377188T3 (es) * 2002-01-18 2012-03-23 Zymogenetics, Inc. Nuevo ligando de citocina ZCYTOR17
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
CA2522894C (en) * 2003-05-31 2013-06-25 Micromet Ag Pharmaceutical composition comprising a bispecific antibody specific for epcam
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
AU2006207945B2 (en) 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
WO2008021976A2 (en) 2006-08-09 2008-02-21 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
MX2007009577A (es) 2005-02-14 2008-01-30 Zymogenetics Inc Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31.
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US20070098715A1 (en) * 2005-03-25 2007-05-03 Seth Ettenberg Antibodies against the tenascin major antigens
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
AU2007254715B2 (en) 2005-05-06 2013-08-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP2759549B1 (en) 2006-09-01 2015-08-19 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
CN101588816B (zh) 2006-10-19 2013-06-19 Csl有限公司 白介素-13受体α1的高亲和性抗体拮抗物
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
BRPI0917459B1 (pt) * 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010027488A2 (en) 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2011065935A1 (en) 2009-11-24 2011-06-03 Cornell University Methods for monoclonal antibody production
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
BR112014001052A2 (pt) 2011-07-22 2017-02-21 Glaxosmithkline Biologicals Sa método para reduzir a agregação de uma proteína, uso de uma composição polianiônica, composição, e, método e processo para a produção de uma composição
EP3765500A2 (en) * 2018-03-16 2021-01-20 Zoetis Services LLC Interleukin-31 monoclonal antibodies for veterinary use

Also Published As

Publication number Publication date
EP3219729A1 (en) 2017-09-20
PT3219729T (pt) 2020-10-23
EP3653645A1 (en) 2020-05-20
ZA201400768B (en) 2015-12-23
HUE051068T2 (hu) 2021-01-28
LT3219729T (lt) 2020-11-25
US9206253B2 (en) 2015-12-08
CA2926379A1 (en) 2013-01-24
US20190389944A1 (en) 2019-12-26
KR20140041858A (ko) 2014-04-04
US8790651B2 (en) 2014-07-29
AR087281A1 (es) 2014-03-12
WO2013011407A1 (en) 2013-01-24
UY34206A (es) 2013-02-28
CN103890009A (zh) 2014-06-25
EP3653645B1 (en) 2024-08-21
KR101742928B1 (ko) 2017-06-01
CY1119475T1 (el) 2018-03-07
CN103890009B (zh) 2017-02-15
KR101613024B1 (ko) 2016-04-18
NZ620031A (en) 2016-03-31
CA2842475C (en) 2018-01-02
ES2827231T3 (es) 2021-05-20
DK2734549T3 (en) 2017-09-11
RS60924B1 (sr) 2020-11-30
CY1123791T1 (el) 2022-03-24
JP2014529295A (ja) 2014-11-06
ES2638340T3 (es) 2017-10-19
DK3653645T3 (da) 2024-09-16
SI3219729T1 (sl) 2020-11-30
MX349053B (es) 2017-07-06
MX2014000803A (es) 2014-03-31
EP3219729B1 (en) 2020-09-09
PL2734549T3 (pl) 2017-11-30
US10526405B2 (en) 2020-01-07
US20130022616A1 (en) 2013-01-24
AU2016203590A1 (en) 2016-06-16
LT2734549T (lt) 2017-09-11
KR20160028488A (ko) 2016-03-11
HRP20171198T1 (hr) 2017-10-20
JP6022563B2 (ja) 2016-11-09
CN105504059B (zh) 2020-08-11
US10421807B2 (en) 2019-09-24
ME02837B (me) 2018-01-20
HRP20201634T1 (hr) 2020-12-25
US20190359702A1 (en) 2019-11-28
AU2012285432A1 (en) 2014-01-30
CA2842475A1 (en) 2013-01-24
CN105504059A (zh) 2016-04-20
SI2734549T1 (sl) 2017-10-30
AU2012285432B2 (en) 2016-06-16
US20140286958A1 (en) 2014-09-25
EP3842456B1 (en) 2024-09-18
US20140315251A1 (en) 2014-10-23
EP2734549A1 (en) 2014-05-28
PT2734549T (pt) 2017-08-29
BR112014001407A8 (pt) 2022-11-08
AU2012285432C1 (en) 2016-12-22
RU2014101250A (ru) 2015-08-27
HUE034282T2 (en) 2018-02-28
BR112014001407A2 (pt) 2017-03-01
RS56268B1 (sr) 2017-11-30
AU2016203590B2 (en) 2017-12-21
US20190092854A1 (en) 2019-03-28
EP3842456A1 (en) 2021-06-30
EP2734549B1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
HK1252895A1 (zh) 識別α-突觸核蛋白的人源化抗體
IL259826A (en) Anti-alphabetatisiar antibody
ZA201400768B (en) Interleukin-31 monoclonal antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
TWI563004B (en) Anti-hxcr1 antibody
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
EP2690111A4 (en) MONOCLONAL ANTI-MOUSE AGGRUS ANTIBODY
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
EP2714074A4 (en) ANTIBODIES AGAINST EMR1